Intertek doubles revenue to £3.3B over 13 years through regulated TIC acquisitions
Intertek doubled revenue to £3.3B from 2010 to 2023 by acquiring testing labs in regulated markets.
Intertek Group, a Large Enterprise Serial Acquirers & Roll-ups company, created value through Market Entry and Customer Expansion and Volume Growth.
Intertek Group (LON: ITRK) entered the 2017–2023 period as one of the four dominant global Testing, Inspection, and Certification firms, alongside SGS, Bureau Veritas, and TÜV. The TIC industry is structurally fragmented: tens of thousands of independent regional labs serve regulated industries where customers cannot legally sell products without third-party certification. Regulation — not customer preference — creates the demand.Intertek had revenue of £2,769.1M in FY2017 and operated across 100+ countries but faced a large addressable market of independent labs that could be acquired to extend geographic and sector coverage. The core opportunity was consolidation of a market where incumbents face almost no pricing pressure (compliance is mandatory) and almost no attrition (switching TIC provider mid-product-cycle creates regulatory risk). Organic growth in TIC tracks GDP and regulatory intensity; inorganic growth via acquisition is the primary path to outperformance. Intertek's existing network gave it infrastructure to absorb acquisitions quickly — acquired labs gain access to global accreditations, IT systems, and cross-selling channels.
Over FY2017–FY2023, Intertek executed a disciplined bolt-on acquisition programme, typically completing 8–15 acquisitions per year in the £5M–£50M range. The acquisition logic was coverage-driven: identify geographies or testing categories where Intertek had no presence and buy the established local incumbent.Key moves in the window: In FY2017, Intertek acquired Alchemy Systems, a food safety training and compliance software company, adding SaaS-based regulatory workflow tools to the food segment, and completed roughly 10 bolt-ons totalling approximately £200M in acquired revenue. In FY2018–2019, Intertek focused on Asia-Pacific and North America, acquiring labs in electronics testing (5G component certification), apparel inspection, and environmental services; revenue reached £2,987.0M in FY2019. In FY2020, the acquisition pace slowed during COVID and revenue dipped to £2,742M, but Intertek used the period to integrate prior acquisitions and protect margins. In FY2021–2022, Intertek re-accelerated, adding softlines and food labs in Southeast Asia, Latin America, and the Middle East where new food safety regulations were creating mandatory testing requirements. By FY2023, revenue reached £3,328.7M, surpassing the pre-COVID FY2019 peak of £2,987.0M.Intertek's integration model is deliberate: acquired labs retain local relationships and accreditations but plug into the global laboratory information management platform and are rebranded within 12–18 months. The "Total Quality Assurance" commercial model — launched in 2014 and extended across the period — shifted customer relationships from transactional pay-per-test toward programme-level retainer contracts spanning multiple categories, improving revenue predictability and switching costs.
~21% Revenue CAGR for 16 Years Through Micro-Cap Scientific Instrument Acquisitions at 4–6x EBIT
27%+ EBITDA Margins Through Decentralized Niche Acquisition Strategy
From FY2017 to FY2023, Intertek grew revenue from £2,769.1M to £3,328.7M. The FY2019 pre-COVID peak of £2,987.0M was exceeded by FY2023, reflecting clean recovery plus incremental acquisition contribution. Over the longer 2010–2023 window, revenue approximately doubled from approximately £1.4B (FY2010: £1,374.2M).Adjusted operating margin was sustained at 16–17.5% through the period, with FY2023 at 16.6% — exceptional for a services business with global laboratory infrastructure. EBITDA margin remained above 20% through the cycle, including the COVID trough. FY2020 revenue declined only 8.2% despite COVID-related factory shutdowns — validation of the regulatory mandate thesis, as food, safety, and energy audits continued. Intertek consistently generated return on capital above 20%, reflecting the asset-light nature of acquisitions where labs are typically leased rather than owned.The acquisition model produced compounding benefits: each lab added not only its own revenue but incremental cross-sell through the network. The TIC business model — where customers face regulatory risk if they switch providers mid-compliance cycle — created multi-year revenue visibility once a customer relationship was established. This recession-resistance and margin durability placed Intertek on a premium valuation with price-to-earnings consistently 25–35x, justified by earnings quality rather than growth rate.
Regulatory mandate as structural demand driver: TIC revenue is non-discretionary in regulated industries. Customers testing food, electronics, or chemicals for export compliance cannot defer testing — they can only switch providers at significant operational risk, eliminating typical sales cycle risk in business services. Global accreditation network: Intertek holds thousands of national and international accreditations including ISO 17025, FDA recognition, and CE marking authority. Acquired labs immediately benefit from these without rebuilding accreditations locally — a 2–3 year shortcut creating immediate uplift on acquired revenue. Fragmented target market: The global TIC industry remains predominantly independent operators, providing a long acquisition runway without competitive concentration risk. Operational leverage from fixed-cost labs: Laboratory infrastructure is largely fixed cost, so adding incremental volume to an acquired lab flows through at high incremental margin. Proprietary LIMS integration infrastructure enabling rapid standardization post-acquisition.
Rollins grows revenue from $1.8B to $3.1B in five years through acquisition-led route density and pricing power